Resource Summary Report

Generated by NIF on Sep 21, 2026

SK-MEL-2

RRID:CVCL_0069
Type: Cell Line

Proper Citation

RRID:CVCL_0069

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0069

Proper Citation: RRID:CVCL_0069

Description: Cell line SK-MEL-2 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Melanoma

Defining Citation: PMID:327080, PMID:833871, PMID:2041050, PMID:2784858, PMID:3335022, PMID:3518877, PMID:6220172, PMID:7718330, PMID:7999427, PMID:8631022, PMID:8755562, PMID:9331090, PMID:10700174, PMID:12068308, PMID:14871852, PMID:15467732, PMID:15748285, PMID:17088437, PMID:18277095, PMID:19372543, PMID:19727395, PMID:20164919, PMID:21725359, PMID:21912889, PMID:22068913, PMID:22347499, PMID:22384151, PMID:22460905, PMID:22628656, PMID:23285177, PMID:23856246, PMID:23933261, PMID:24279929, PMID:24576830, PMID:24670534, PMID:25485619, PMID:25728708, PMID:25877200, PMID:26589293, PMID:27377824, PMID:27397505, PMID:27533468, PMID:27807467, PMID:28196595, PMID:30894373, PMID:30971826, PMID:31068700, PMID:31733513, PMID:31978347, PMID:35839778, PMID:38861359

Comments: Population: Caucasian., From: Memorial Sloan Kettering Cancer Center; New York; USA., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SK-MEL-2

Synonyms: SK-Mel-2, SK-Mel 2, SK-mel-2, SK-MEL2, SK.MEL.2, SK Mel 2, SK MEL 2, SKMEL-2, SKMEL2, SKmel2, SK-ML2, SKml2

Cross References: BTO:BTO_0003476, CLO:CLO_0009041, EFO:EFO_0002079, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-3610, ATCC:HTB-68, BioGRID_ORCS_Cell_line:1012, BioSample:SAMN03471882, BioSample:SAMN03472752, BioSample:SAMN05292464, BioSample:SAMN10988256, cancercelllines:CVCL_0069, CancerTools:161915, Cell_Model_Passport:SIDM00082, CGH-DB:9322-4, ChEMBL-Cells:CHEMBL3307743, ChEMBL-Targets:CHEMBL614917, CLS:300423, Cosmic:724824, Cosmic:875885, Cosmic:897468, Cosmic:905235, Cosmic:905955, Cosmic:974073, Cosmic:974257, Cosmic:1006555, Cosmic:1022288, Cosmic:1044266, Cosmic:1045411, Cosmic:1067222, Cosmic:1092632, Cosmic:1132585, Cosmic:1155283, Cosmic:1175871, Cosmic:1303053, Cosmic:1305367, Cosmic:1458964, Cosmic:1459662, Cosmic:1477419, Cosmic:1669129, Cosmic:1995633, Cosmic:1998475, Cosmic:2159450, Cosmic:2479250, Cosmic-CLP:905955, DepMap:ACH-001190, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:905955, GEO:GSM2109, GEO:GSM50204, GEO:GSM50266, GEO:GSM188225, GEO:GSM188255, GEO:GSM188314, GEO:GSM743467, GEO:GSM750824, GEO:GSM799356, GEO:GSM799419, GEO:GSM844688, GEO:GSM844689, GEO:GSM847115, GEO:GSM887585, GEO:GSM888668, GEO:GSM1153426, GEO:GSM1181281, GEO:GSM1181359, GEO:GSM1670437, GEO:GSM1671997, GEO:GSM1672003, GEO:GSM1672044, GEO:GSM1672075, GEO:GSM1672083, GEO:GSM1672088, GEO:GSM1672104, GEO:GSM1672117, GEO:GSM1672126, GEO:GSM2124650, IARC_TP53:18086, KCLB:30068, LINCS_LDP:LCL-1256, NCI-DTP:SK-MEL-2, PharmacoDB:SKMEL2_1394_2019, PRIDE:PXD003539, PRIDE:PXD005942, PRIDE:PXD005946, PRIDE:PXD030206, PRIDE:PXD030304, Progenetix:CVCL_0069, PubChem_Cell_line:CVCL_0069, SKY/M-FISH/CGH:2820, Wikidata:Q54953905

ID: CVCL_0069

Record Creation Time: 20220427T221545+0000

Record Last Update: 20260920T005749+0000

Ratings and Alerts

No rating or validation information has been found for SK-MEL-2.

No alerts have been found for SK-MEL-2.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 362 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Pyun WY, et al. (2026) Nutrient Availability Dictates Cancer Metabolism-Based Therapeutic Responses to Nononcology Drugs. Cancer research, 86(5), 1194.

Watterson A, et al. (2026) CRISPR screens in the context of immune selection identify CHD1 and MAP3K7 as mediators of cancer immunotherapy resistance. Cell reports. Medicine, 7(1), 102565.

Baars B, et al. (2026) RAS Mutation-Specific Responses to Paralog- and State-Selective RAS Inhibitors. Molecular cancer research : MCR, 24(1), 60.

O'Loughlin TA, et al. (2026) mTORC1 activity suppresses ferroptosis through a SCARB1-dependent HDL-tocopherol uptake pathway. Molecular cell, 86(8), 1546.

Gadal S, et al. (2025) Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations That Overcome Its Feedback Inhibition of RAC1 and Migration. Cancer research, 85(9), 1611.

Cerqua M, et al. (2025) The integrated stress response drives MET oncogene overexpression in cancers. The EMBO journal, 44(4), 1107.

Imumkachi N, et al. (2025) Tryptophan-Conjugated Carbon Dots with Enhanced Cellular Uptake as a Potential Drug Delivery System for Melanoma. ACS applied bio materials, 8(12), 11047.

Boucher J, et al. (2025) CDK12 inhibition reveals melanoma dependence on the RUNX1/CBF? complex for genomic stability. Cell reports, 44(11), 116495.

Fu X, et al. (2025) A cancer-specific antigen drives histone acetylation by stabilizing the acetyltransferases. Cell reports, 44(10), 116408.

Panda PK, et al. (2025) BCL-XL Protects ASS1-Deficient Cancers from Arginine Starvation-Induced Apoptosis. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(7), 1333.

Kim DY, et al. (2025) Identification of UBE3C as an E3 ubiquitin ligase for mutant BRAF. Life sciences, 378, 123827.

Parihar K, et al. (2025) Tissue-dependent mechanosensing by cells derived from human tumors. npj biological physics and mechanics, 2(1), 19.

Foote JB, et al. (2025) A Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth and Induces Antitumor Immunity in Gastrointestinal Cancer. Cancer research, 85(5), 956.

Mizuno Y, et al. (2025) Focal Adhesion Kinase-Dependent Reprogramming of IFN-? Signaling through PYK2 Coinhibition Sensitizes Melanoma to Immune Checkpoint Blockade. The Journal of investigative dermatology.

Kunkel MW, et al. (2024) HTS384 NCI60: The Next Phase of the NCI60 Screen. Cancer research, 84(15), 2403.

Mukherjee S, et al. (2024) "Radical" differences between two FLIM microscopes affect interpretation of cell signaling dynamics. iScience, 27(7), 110268.

Weinstein HNW, et al. (2024) RPL22 is a tumor suppressor in MSI-high cancers and a splicing regulator of MDM4. Cell reports, 43(8), 114622.

Tubita A, et al. (2024) Latent-Transforming Growth Factor ?-Binding Protein 1/Transforming Growth Factor ?1 Complex Drives Antitumoral Effects upon ERK5 Targeting in Melanoma. The American journal of pathology, 194(8), 1581.

Cai C, et al. (2024) NRAS Mutant Dictates AHCYL1-Governed ER Calcium Homeostasis for Melanoma Tumor Growth. Molecular cancer research : MCR, 22(4), 386.

Yue C, et al. (2024) The role of PKP1 in tumor progression in melanoma: Analysis of a cell adhesion-related model. Environmental toxicology, 39(2), 915.